Equity research · The long view

Investment research through a long-term owner's lens

The Zen Horizon Framework, dissecting the business quality, moats, and intrinsic value of AI, technology, and global equities — with a clear read on the margin of safety.

1005 reports14 topics991 tickers
Latest Research
More research
28/100 Watch DENTSPLY SIRONA: A Real Dental Incumbent, but the Repricing Is Permanent and 13.02 USD Already Prices Base Value DENTSPLY SIRONA is a broad, diversified dental supplier spanning consumables and endodontics, implants, imaging and chairside CAD/CAM equipment. Sales of 3.68 billion USD in 2025 produced free cash flow of only 104 million USD, and market value has fallen from about 11.11 billion USD at end-2016 to roughly 2.55 billion USD. Rating Watch: the discount is a permanent repricing of business quality, governance trust and category relevance rather than a cyclical dip, so at 13.02 USD the stock already trades near base value and the ideal buy zone is 7 to 9 USD. DENTSPLY SIRONA Inc.XRAY · USMedical DevicesJul 28, 2026 53/100 Hold Innovent Biologics: The China Platform Is Real, but the Price Already Pre-Pays the Obesity Curve Innovent Biologics is a China biopharma with 18 approved products, an oncology commercial base that produced RMB11.93 billion of 2025 product revenue, and a new obesity franchise built on mazdutide. 2025 brought the first full-year profit of RMB813.6 million, but headline operating cash flow of RMB10.0 billion was flattered by a RMB7.64 billion contract-liability inflow tied to Takeda's upfront. Rating Hold: at HK$89.35 and roughly 10 times trailing sales, the price already pre-pays much of the obesity and licensing upside before the economics are proven. Innovent Biologics, Inc.1801 · HKPharmaceuticalsJul 28, 2026 52/100 Hold Oracle Corporation Oracle is an enterprise software and cloud infrastructure vendor whose database and applications cash engine is now funding a massive AI data-center build-out. Fiscal 2026 revenue reached 67.4 billion USD and remaining performance obligations hit 638 billion USD, but capex of 55.7 billion USD drove free cash flow to negative 23.7 billion USD, and S&P cut the credit rating to BBB- in July. Rating Hold: the 34% fall from the previous report's 181 USD reference point has absorbed much of the financing anxiety, but at 119.90 USD there is still no meaningful margin of safety for new money. Oracle CorporationORCL · USSoftware & InternetJul 28, 2026 49/100 Watch Tesla: The Franchise Is Real, but $900 Billion of the Market Cap Rests on Robotaxi Economics No One Has Disclosed Tesla is an integrated EV and battery-storage manufacturer whose trailing-twelve-month revenue now exceeds $100 billion, and it is redirecting that industrial base to fund robotaxis, AI infrastructure and humanoid robots. Q2 2026 revenue rose 26% to $28.236 billion while operating income fell 57% to $398 million, operating margin dropped to 1.4%, capex jumped 142% to $5.789 billion and free cash flow swung to negative $1.092 billion, with 2026 capex now guided above $25 billion. Rating Watch: the visible auto, energy and charging businesses are worth roughly $140 to $190 billion against a $1.095 trillion market cap, which leaves about $905 to $955 billion of the price resting on robotaxi and Optimus economics the company has not disclosed. Tesla, Inc.TSLA · USElectric VehiclesJul 28, 2026
Insights
All insights
  1. The Mention Map, July 2026: Four Gravity Centers, Four Holes Jul 26, 2026
  2. AI Circular Financing: Stroke of Genius or the Ponzi of the Century? We Counted Every Dollar in the Loop Jul 7, 2026
  3. Growth Score Index, 2026 Q2: Only One Company in 897 Clears the Bar Jul 3, 2026
  4. Has the Memory Supercycle Topped? Our 71 Chip Scorecards Had the Answer Before the Crash Jun 15, 2026
Featured Topics
All 14 topics

Cancer · Rare Disease · Hard-to-Treat Frontiers

108 tickers

Targeted / immuno / cell / gene / nucleic-acid / radiopharmaceuticals: a map of the frontier therapies attacking high-unmet-need diseases, with the global and Chinese players building them

Niche Champions Across Every Industry

90 tickers

Companies that own a narrow track, ranking first or top-three globally and holding real pricing power: niche champions in critical links of the chain. The framing follows Hermann Simon's "hidden champions," but relaxes his size and obscurity thresholds (no cap on size, no requirement to stay low-profile). What counts is how narrow the track is and how deeply entrenched the position, laid out across eight functional domains.

Serenity's Bottleneck Investing Method

43 tickers

A retail "optical-comms bottleneck hunter" abroad and her five-factor framework, plus the chokepoint names she has called out publicly across industries

Don't see a stock you follow? Request custom research